BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 24210228)

  • 21. Prognostic significance of total lesion glycolysis in patients with advanced non-small cell lung cancer receiving chemotherapy.
    Zaizen Y; Azuma K; Kurata S; Sadashima E; Hattori S; Sasada T; Imamura Y; Kaida H; Kawahara A; Kinoshita T; Ishibashi M; Hoshino T
    Eur J Radiol; 2012 Dec; 81(12):4179-84. PubMed ID: 22884163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fibroblast growth factor 2--a predictor of outcome for patients irradiated for stage II-III non-small-cell lung cancer.
    Rades D; Setter C; Dahl O; Schild SE; Noack F
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):442-7. PubMed ID: 20950963
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical significance of ERCC2 haplotype-tagging single nucleotide polymorphisms in patients with unresectable non-small cell lung cancer treated with first-line platinum-based chemotherapy.
    Kim SH; Lee GW; Lee MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY
    Lung Cancer; 2012 Sep; 77(3):578-84. PubMed ID: 22608006
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic significance of weight gain during definitive chemoradiotherapy for locally advanced non-small-cell lung cancer.
    Sher DJ; Gielda BT; Liptay MJ; Warren WH; Batus M; Fidler MJ; Garg S; Bonomi P
    Clin Lung Cancer; 2013 Jul; 14(4):370-5. PubMed ID: 23260389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic score for second-line chemotherapy of advanced non-small-cell lung cancer: external validation in a phase III trial comparing vinflunine with docetaxel.
    Di Maio M; Krzakowski M; Fougeray R; Kowalski DM; Gridelli C
    Lung Cancer; 2012 Jul; 77(1):116-20. PubMed ID: 22361218
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic model to predict outcomes in non-small cell lung cancer patients with erlotinib as salvage treatment.
    Kim ST; Lee J; Sun JM; Park YH; Ahn JS; Park K; Ahn MJ
    Oncology; 2010; 79(1-2):78-84. PubMed ID: 21071994
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinicopathological factors affecting progression-free survival of patients with previously treated advanced non-small cell lung cancer after S-1 therapy with or without bevacizumab.
    Masago K; Fujita S; Hata A; Kaji R; Ohtsuka K; Okuda C; Takeshita J; Katakami N
    Anticancer Res; 2014 Dec; 34(12):7467-72. PubMed ID: 25503189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
    Xu TP; Shen H; Liu LX; Shu YQ
    Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Study of prognostic factors in patients with stage I non-small cell lung cancer].
    Jiang ZQ; Jiang GL; Shi DR; Zhang RX; Fu XL; Qian H
    Zhonghua Zhong Liu Za Zhi; 2004 Jun; 26(6):364-8. PubMed ID: 15312349
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic factors in patients with advanced non-small cell lung cancer: data from the phase III FLEX study.
    Pirker R; Pereira JR; Szczesna A; von Pawel J; Krzakowski M; Ramlau R; Vynnychenko I; Park K; Eberhardt WE; de Marinis F; Heeger S; Goddemeier T; O'Byrne KJ; Gatzemeier U
    Lung Cancer; 2012 Aug; 77(2):376-82. PubMed ID: 22498112
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Weight gain in advanced non-small-cell lung cancer patients during treatment with split-course concurrent chemoradiotherapy is associated with superior survival.
    Gielda BT; Mehta P; Khan A; Marsh JC; Zusag TW; Warren WH; Fidler MJ; Abrams RA; Bonomi P; Liptay M; Faber LP
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):985-91. PubMed ID: 20932684
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials.
    Mandrekar SJ; Schild SE; Hillman SL; Allen KL; Marks RS; Mailliard JA; Krook JE; Maksymiuk AW; Chansky K; Kelly K; Adjei AA; Jett JR
    Cancer; 2006 Aug; 107(4):781-92. PubMed ID: 16847887
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence and effectiveness of first-, second-, and third-line systemic therapy in a cohort of unselected patients with advanced non-small cell lung cancer.
    Zietemann V; Duell T
    Lung Cancer; 2011 Jul; 73(1):70-7. PubMed ID: 21095039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical assessment of patients with advanced non-small-cell lung cancer eligible for second-line chemotherapy: a prognostic score from individual data of nine randomised trials.
    Di Maio M; Lama N; Morabito A; Smit EF; Georgoulias V; Takeda K; Quoix E; Hatzidaki D; Wachters FM; Gebbia V; Tsai CM; Camps C; Schuette W; Chiodini P; Piccirillo MC; Perrone F; Gallo C; Gridelli C
    Eur J Cancer; 2010 Mar; 46(4):735-43. PubMed ID: 20045311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Factors associated with long-term survival of patients with advanced non-small cell lung cancer.
    Giroux Leprieur E; Lavole A; Ruppert AM; Gounant V; Wislez M; Cadranel J; Milleron B
    Respirology; 2012 Jan; 17(1):134-42. PubMed ID: 21943088
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy.
    Berardi R; Rinaldi S; Santoni M; Newsom-Davis T; Tiberi M; Morgese F; Caramanti M; Savini A; Ferrini C; Torniai M; Fiordoliva I; Bower M; Cascinu S
    Oncotarget; 2016 May; 7(18):26916-24. PubMed ID: 27029035
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pulmonary function parameters as prognostic factors in advanced non-small cell lung cancer.
    Rančić M; Ristić L; Rančić S; Radović M; Ćirić Z
    Med Glas (Zenica); 2014 Feb; 11(1):58-65. PubMed ID: 24496342
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinicopathological and prognostic features of operable non-small cell lung cancer patients with diabetes mellitus.
    Kaseda K; Hishida T; Masai K; Asakura K; Hayashi Y; Asamura H
    J Surg Oncol; 2021 Jan; 123(1):332-341. PubMed ID: 33002203
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is diabetes mellitus a prognostic factor for survival in patients with small cell lung cancer?
    Inal A; Kaplan MA; Kucukoner M; Urakci Z; Karakus A; Nas N; Guven M; Isikdogan A
    Asian Pac J Cancer Prev; 2012; 13(4):1491-4. PubMed ID: 22799354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic factors in older patients with advanced non-small cell lung cancer in China.
    Su Q; Sun YP; Liu YH; Li Z; Yang HY; Sun ZG; Cao BW; Jia JH
    Tumori; 2014; 100(1):69-74. PubMed ID: 24675494
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.